Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Guselkumab in Healthy Japanese Males
NCT03536325Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of guselkumab in plaque psoriasis (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability. Started May 2018; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03536325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536325.